A recently released inmate looks at the effects of quarantine—and stigma
As long-acting treatment and prevention begins to enter communities, we must move toward dismantling systemic racism
Impressive results from two efficacy trials of a long-acting form of the integrase inhibitor cabotegravir (CAB LA) have boosted prospects for long-acting HIV pre-exposure prophylaxis (PrEP). In both cases, CAB LA proved superior to oral Truvada PrEP (see table below).
PACHA appointee Tori Cooper discusses the needs of the transgender community with PA associate editor Enid Vázquez
“HIV don’t care if you are black or white, or straight or gay.” —Eunice Marshall